论文部分内容阅读
应用免疫组化技术对乳腺导管上皮轻、中度非典型增生（ＡＩＤＨ）６５例（轻中度组）、重度 ＡＩＤＨ ３０例（重度组）、浸润性导管癌 ４０例（导管癌组）和正常乳腺２０例（正常组）进行 ａｃｔｉｎ蛋白的检测。结果：（１）各组 ａｃｔｉｎ表达阳性率分别为正常组１００％（２０／２０例），轻、中度组１００％（６５／６５例），重度组７３．３％（２２／３０例），导管癌组１７．５％（７／４０例）。正常组和轻、中度组相同，其它各组之间比较均有显著性差异（ Ｐ＜ ０． ０５）。（ ２）阳性细胞（肌上皮细胞）的分布方式：正常组和轻、中度组的肌上皮细胞皆以连续性分布为主（分别占９０％和８１．４％），阴性表达率分别为１．５％和５．３％。重度组肌上皮细胞呈连续性分布者仅为２２．５％，１９．６％呈断续性分布和１８．６％呈零星散在，阴性表达率为 ３９． ３％。导管癌组的阴性表达率高达 ９６． ５％，个别呈现 ａｃｔｉｎ阳性的癌巢的上皮也多零星散在（ ２． ７％）或断续性分布（０．８％）。各组之间阳性细胞的分布方式均有显著性差异（Ｐ＜０．０５）或非常显著性差异（均Ｐ＜０．０１）。提示： ａｃｔｉｎ免疫组化检测可用作评估乳腺 ＡＩＤＨ程度及重度 ＡＩＤＨ恶变潜能的一
Immunohistochemical techniques for 65 cases of mild or moderate atypical hyperplasia (AIDH) in the ductal epithelium of the breast (light to moderate group), 30 cases of severe AIDH (heavy group), 40 cases of invasive ductal carcinoma (catheter carcinoma group) and normal The actin protein was detected in 20 cases of the breast (normal group). Results: (1) The positive rate of actin expression in each group was 100% (20/20) in normal group, 100% (65/65) in mild and moderate group, and 73.3% (22/30) in severe group. 17.5% of catheter cancer patients (7/40 patients). The normal group was the same as the mild and moderate groups, and there was a significant difference between the other groups (P<0.05). (2) Distribution pattern of positive cells (myoepithelial cells): The myoepithelial cells in the normal group and the light and moderate groups were mainly distributed in a continuous manner (90% and 81.4%, respectively). The negative expression rates were 1.5% and 5.3%. The continuous distribution of myoepithelial cells in the severe group was only 22.5%, 19.6% was intermittently distributed and 18.6% was sporadic, and the negative expression rate was 39. 3%. The negative rate of ductal carcinoma was 96. In 5%, the epithelium of actin-positive cancer nests was also sporadic (2.7%) or discontinuously distributed (0.8%). The distribution pattern of positive cells in each group was significantly different (P<0.05) or very significant difference (all P<0.01). Note: actin immunohistochemistry can be used to assess the degree of breast AIDH and severe AIDH malignancy potential